reason report
china food
bottom line remain outperform agil given well-
diversifi posit across healthcar growth end-market
pharma dx genom lead posit chemic
ahead us street estim guid
within street estim suggest conservat given
china food rev impact still on-going weak chemic
rev spend major impact felt
lsag instrument busi rev declin qtr
china rev declin low singl digit deliv
growth off-set came acg crosslab group rev
deliv org growth quarter dgg busi
rev deliv growth back growth nasd
oligo patholog us long-term outlook agil
lever china food busi improv stabil even
importantli nasd busi goe run rate near
next year half bake org revenue guid
remain op agil increas pt
lsag acg deliv beat china food busi
continu weigh agil deliv beat vs estim driven
better expect lsag vs crosslab growth
vs strong end-market perform pharma despit
difficult comp org growth continu weigh
weak capit spend environ persist china food
test headwind china lsd although still
lsd year pharma busi china dd year
despit much discuss disrupt strong expens manag
margin expans crosslab segment y/i led ep
upsid quarter
nasd busi bright spot like exceed expect
long-term agil current deliv close oligo
busi leader market suppli raw ingredi
gene therapi drug manufactur forecast busi reach
half growth bake current
guid provid room upsid view recal one two
lead supplier market one nitto hope scale
capac co facil uniformli throughout cell analysi
busi annual grow anoth growth
driver come quarter two tailwind develop
improv buy environ better-than-expect
china food rebound stabil quarterli run
rate would repres solid upsid initi guid view
price-to-earnings lt ep growth
life scienc tool diagnost
year price history/av daili volume mil
compani inform svb leerink llc research
revenu us million ep exclud item amort intang
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
guid still conserv top-lin estim move higher
ep reflect modest leverag agil guid revenu
organ revenue growth rang
revenu estim rais slightli reflect
org growth rang fx assumpt organ revenue
growth top guid believ upsid could
occur ramp contribut nasd oligo busi
allevi china food busi macro headwind
bottom line ep slightli lower underpin
bp op margin expans driven disciplin cost manag
rate agil share outperform price target view agil
posit believ compani hold lead posit environment chemic
food test market around world maintain well-diversifi posit across
healthcar biopharma life scienc tool lst diagnost compani also repres
margin expans opportun medium longer term spin-off keysight
electron manag busi becom pure-play life scienc tool lst compani
agil continu deliv improv adjust oper margin despit growth initi
believ achiev exceed longer term leadership
ceo mcmullen agil compet aggress multipl market deliv solid growth
biopharma sale maintain either posit across
end-market includ food environment chemical/energi emerg market post
solid growth agil posit capit given sizabl exposur geographi
intuvo product cycl could repres opportun current under-
appreci view agil repres compani develop core root
industri chemic electron market year transform life
scienc tool technolog leader diversifi access lead end-market
agil share current trade ev/ebitda under-valued view
compar life scienc tool peer group
averag believ ev/ebitda valuat provid best measur
agil valu price target expect agil trade line
averag lst group ev/ebitda multipl result appli ev/
ebitda multipl ebitda estim arriv pt
primari risk price target includ
biopharma declin pose greatest risk agil margin expans plan declin
biopharma fund could highli impact agil revenu given revenu lever
biopharma industri believ gener biopharma price risk mute given
elect outcom howev impact regulatori chang could see
biopharma compani becom cautiou spend could impact capit
equip purchas includ agil slowdown biopharma fund would
result downsid risk estim valuat biomolecul forecast ramp
drug market mid-teen believ prolifer drive
use agil mass spectromet character molecul pronounc
slowdown biopharma core growth requir margin expans would
slowdown global budget research could pose downsid risk forecast tighten
budget govern academ fund could result lower revenu rel
estim agil much academ government exposur
competitor nevertheless slowdown academ spend could
headwind plan margin expans assum expect core growth furthermor
restrict global budget could result shift focu strategi growth could
increas oper risk declin government spend could risk downsid
forecast growth nih spend flat low-single-digit
soft demand emerg market could derail growth forecast geopolit risk emerg
market could disrupt oper downsid risk valuat forecast geopolit
risk could also impact agil strategi creat higher barrier entri exist futur
market agil oper numer intern market includ china middl east
europ macroeconom impact chines market could lead declin compani
revenu regul chines polici could also caus restrict oper lead
lower activ china question remain china concern detail
headwind could emerg polici risk
continu volatil energi chemic sector could impact growth agil
consider exposur revenu chemic energi industri agil expect
recoveri next year continu volatil crude oil could result downsid risk
agil expect low-single-digit growth next year volatil oil price could impact
budget next year spend certain countri dictat commod price
would lead lower spend chemic energi
dollar million except per share data
good sold
sg sale
 sale
oper expens sale
compani report svb leerink estim
